Comprehensive analyses of m1A regulator-mediated modification patterns determining prognosis in lower-grade glioma (running title: m1A in LGG)

Bibliographic Details
Title: Comprehensive analyses of m1A regulator-mediated modification patterns determining prognosis in lower-grade glioma (running title: m1A in LGG)
Authors: Kunjian Lei, Yilei Sheng, Min Luo, Junzhe Liu, Chuandong Gong, Shigang Lv, Wei Tu, Minhua Ye, Miaojing Wu, Bing xiao, Hua Fang, Haitao Luo, Xinjun Liu, Xiaoyan Long, Xingen Zhu, Kai Huang, Jingying Li
Source: Heliyon, Vol 10, Iss 6, Pp e27510- (2024)
Publisher Information: Elsevier, 2024.
Publication Year: 2024
Collection: LCC:Science (General)
LCC:Social sciences (General)
Subject Terms: Lower-grade glioma, N1-methyladenosine, Prognostic signature, ssGSEA, Tumor immune, Science (General), Q1-390, Social sciences (General), H1-99
More Details: N1-methyladenosine (m1A) modification is a crucial post-transcriptional regulatory mechanism of messenger RNA (mRNA) in living organisms. Few studies have focused on analysis of m1A regulators in lower-grade gliomas (LGG). We employed the Nonnegative Matrix Factorization (NMF) technique on The Cancer Genome Atlas (TCGA) dataset to categorize LGG patients into 2 groups. These groups exhibited substantial disparities in terms of both overall survival (OS) and levels of infiltrating immune cells. We collected the significantly differentially expressed immune-related genes between the 2 clusters, and performed LASSO regression analysis to obtain m1AScores, and established an m1A-related immune-related gene signature (m1A-RIGS). Next, we categorized all patients with LGG into high- and low-risk subgroups, predictive significance of m1AScore was confirmed by conducting univariate/multivariate Cox regression analyses. Additionally, we confirmed variations in immune-related cells and ssGSEA and among the high-/low-risk subcategories in the TCGA dataset. Finally, our study characterized the effects of MSR1 and BIRC5 on LGG cells utilizing Edu assay and flow cytometry to explore the effects of modulation of these genes on glioma. The results of this study suggested that m1A-RIGS may be an excellent prognostic indicator for patients with LGG, and could also promote development of novel immune-based treatment strategies for LGG. Additionally, BIRC5 and MSR1 may be potential therapeutic targets for LGG.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2405-8440
Relation: http://www.sciencedirect.com/science/article/pii/S2405844024035412; https://doaj.org/toc/2405-8440
DOI: 10.1016/j.heliyon.2024.e27510
Access URL: https://doaj.org/article/ddbf8f40b0664490b80071d83b194972
Accession Number: edsdoj.bf8f40b0664490b80071d83b194972
Database: Directory of Open Access Journals
More Details
ISSN:24058440
DOI:10.1016/j.heliyon.2024.e27510
Published in:Heliyon
Language:English